0000950170-24-062599.txt : 20240520
0000950170-24-062599.hdr.sgml : 20240520
20240520185050
ACCESSION NUMBER: 0000950170-24-062599
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240516
FILED AS OF DATE: 20240520
DATE AS OF CHANGE: 20240520
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DAWES KAREN A
CENTRAL INDEX KEY: 0001261506
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-14656
FILM NUMBER: 24966438
MAIL ADDRESS:
STREET 1: 579 BELLEVUE AVE
CITY: NEWPORT
STATE: RI
ZIP: 02840
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REPLIGEN CORP
CENTRAL INDEX KEY: 0000730272
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 042729386
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41 SEYON STREET
STREET 2: BUILDING 1, SUITE 100
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 7814499560
MAIL ADDRESS:
STREET 1: 41 SEYON STREET
STREET 2: BUILDING 1, SUITE 100
CITY: WALTHAM
STATE: MA
ZIP: 02453
4
1
ownership.xml
4
X0508
4
2024-05-16
0000730272
REPLIGEN CORP
RGEN
0001261506
DAWES KAREN A
C/O REPLIGEN CORPORATION
41 SEYON ST., BLDG 1, STE 100
WALTHAM
MA
02453
true
false
false
false
false
Common Stock
2024-05-16
4
A
false
803
0.00
A
88170
D
Stock Option (Right to Buy)
171.03
2024-05-16
4
A
false
1576
0.00
A
2025-05-16
2034-05-16
Common Stock
1576
1576
D
Ms. Dawes was awarded 803 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 16, 2025, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
Award vests in full on the earlier of May 16, 2025, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
/s/ Kimberly Brown (Attorney in Fact)
2024-05-20